DOCSLIB.ORG

Attenuated 5-Hydroxytryptamine Receptor-Mediated Responses in Aortae from Streptozotocin-Induced Diabetic Rats G.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Attenuated 5-Hydroxytryptamine Receptor-Mediated Responses in Aortae from Streptozotocin-Induced Diabetic Rats G.M Br. J. Pharmacol. (1994), 111, 370-376 '." Macmillan Press Ltd, 1994 Attenuated 5-hydroxytryptamine receptor-mediated responses in aortae from streptozotocin-induced diabetic rats G.M. James, 1W.C. Hodgson, E.A. Davis & 2J.M. Haynes Department of Pharmacology, Monash University, Clayton, Victoria, Australia, 3168 1 This study was designed to examine further the attenuated contractile responses to 5-hydroxy- tryptamine (5-HT) previously observed in aortae from diabetic rats. 2 Cumulative concentration-response curves to 5-HT, and the 5-HT receptor agonists, at-methyl 5-HT (a-Me-5-HT, 5-HT21lc agonist), (± )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 5-HT21IC agonist) and 5-carboxamidotryptamine (5-CT, 5-HTIA/1B/1D agonist), were examined in endothelium- intact and -denuded aortae from 2-week streptozotocin (STZ)-diabetic and control rats. 3 In endothelium-intact and -denuded aortae from diabetic rats, maximum responses to 5-HT and a-Me-5-HT were significantly reduced compared to those of aortae from control rats. Responses to these agonists were inhibited by the 5-HT21lc receptor antagonist, ketanserin (0.1 jAM). 4 The attenuated responses to 5-HT of aortae from diabetic rats were normalized by chronic insulin treatment of the rats (5 units day-', s.c.), but not by altering the glucose concentration of the bathing fluid. 5 The nitric oxide synthase inhibitor N-nitro-L-arginine (NOLA, 0.1 mM) significantly potentiated responses to both 5-HT and a-Me-5-HT in endothelium-intact aortae. However, the difference between maximum responses of aortae from diabetic and control rats was still evident in the presence of NOLA. 6 Endothelium-intact rings, in the presence of ketanserin (0.1 tiM) and preconstricted with the throm- boxane A2-mimetic, U46619 (0.1-0.3jIM), from control and diabetic rats, did not relax to cumulative additions of 5-HT (1 nM-30 jM). 7 Contractile responses to DOI were obtained only in endothelium-denuded aortae, and in endo- thelium-intact aortae in the presence of NOLA, from control rats. 8 Contractile responses to 5-CT were obtained only in endothelium-denuded aortae from both control and diabetic rats, and in endothelium-intact aortae in the presence of NOLA, from control rats. 9 [3H]-ketanserin binding studies showed that there was no significant change in the affinity or density of [3H]-ketanserin for binding sites in membrane preparations of aortae from control and diabetic rats. 10 These results suggest that 5-HT contracts aortae from rats via 5-HT2,,c receptor activation. However, the simultaneous release of EDRF from endothelial cells in response to 5-HT does not appear to be receptor-mediated. The attenuated contractile responses observed to 5-HT in aortae from 2-week diabetic rats do not appear to be mediated by changes in either endothelial cell function or an alteration in 5-HT receptor affinity or density. Keywords: Diabetes mellitus; rat aortae; endothelium; 5-hydroxytryptamine; N-nitro-L-arginine Introduction Methods Previous work from our laboratory has shown that contrac- Male Wistar rats (300-420 g) were treated with STZ (60 mg tile responses to the 5-hydroxytryptamine (5-HT) receptor kg-', i.v.) or vehicle (50 mM citrate buffer) under 4% halo- agonists ( ± )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoprop- thane anaesthesia (2: 1 02/N20). The animals were then ane (DOI) and 5-HT are attenuated in aortic rings from housed in treatment pairs, being allowed free access to food streptozotocin (STZ)-diabetic rats (Sikorski et al., 1993). This and water at all times. Rat body weights and blood glucose latter finding supported the earlier work of Hagen et al. levels were measured on the day of STZ or citrate buffer (1985) and Head et al. (1987). However, the mechanism(s) administration and again after 2 weeks. Only rats displaying behind this abnormality has yet to be elucidated. We have elevated blood glucose levels (> 16 mM, Ames Minilab 1) postulated that functional and/or structural changes of the after 2 weeks were considered to be diabetic. Vehicle control endothelium of vessels from diabetic rats are unlikely to be rats had blood glucose levels of between 3-8 mM when tested responsible for these changes but that a downregulation of at the same time. After 2 weeks, a STZ-induced diabetic and the 5-HT receptor population in aortae from diabetic rats a control animal were killed, and 5 mm rings cut from each may contribute (Sikorski et al., 1993). The aim of the present descending thoracic aorta. Where indicated, endothelial cells study was to identify further the mechanisms underlying the were removed from aortae by rubbing the intimal surface attenuated response to 5-HT receptor agonists of isolated with thin wire. Rings were placed in 15 ml organ baths aortae from 2-week STZ-diabetic rats. This included examin- containing Krebs solution of the following composition (mM): ing the effects of altering the glucose level of the physiolog- NaCl 118.4, KCl 4.7, CaC12 2.5, NaHCO3 25.0, KH2PO4 1.2, ical solution, chronic insulin administration and radioligand MgSO4.7H20 1.2 and glucose 11.1 Where indicated, high- binding studies. glucose Krebs consisted of Krebs solution with 30 mM glu- cose. Physiological solutions were maintained at 37°C, and bubbled with 5% CO2 in 02. Rings were placed under 10 g resting tension throughout the experiment, as this approx- Author for correspondence. imates the physiological wall tension (Fulton et al., 1991; 2 Present address: Department of Medicine, Repatriation Hospital, Sikorski et al., 1993). After 1 h equilibration, a submaximal Bundoora, Victoria, Australia, 3083. concentration of phenylephrine (0.3 fiM) was added to the ATTENUATED 5-HT CONTRACTILE RESPONSES IN DIABETES 371 bath. At the plateau of contraction, acetylcholine (10 LM) Binding analysis was added. The presence of functional endothelial cells was indicated by subsequent relaxation. Following this procedure, Data from both saturation and competition studies were a single cumulative concentration-response curve was con- analysed initially using the computer programme EBDA structed, on each tissue, either in the presence or absence of (McPherson, 1983), to obtain estimates of BmaX KD and Ki antagonists/inhibitors. NOLA was allowed to equilibrate for and then LIGAND (Munson & Rodbard, 1980), to obtain 15 min before the addition of any agonist. Ketanserin and final parameter estimates ( s.e.mean) of B.., KD and Ki. indomethacin were allowed 30 min equilibration. Drugs Insulin treatment The following drugs were used: acetylcholine chloride (Sigma), Where indicated, STZ-treated rats were injected with a single 5-carboxamidotryptamine maleate (Glaxo), (± )-l-(2,5-dime- daily dose of Lente MC insulin zinc suspension (5 units thoxy4-iodophenyl)-2-aminopropane hydrochloride (Research day-', s.c.) commencing on the second day after STZ ad- Biochemicals Inc.), 5-hydroxytryptamine creatine sulphate ministration (Hodgson & King, 1992). (Sigma), iproniazid P04 (Sigma), indomethacin (Sigma), insu- lin (Lente MC zinc suspension, CSL-Novo), ketanserin tartrate (Janssen), x-methyl-5-hydroxytryptamine maleate (Research Binding studies Biochemicals Inc.), methysergide maleate (Sandoz), N-nitro- L-arginine (Sigma), phenylephrine HCl (ICN Pharmaceuti- Tissue preparation The remaining segments of thoracic aor- cal), streptozotocin (Sigma), U-0521 (3',4'-dimethyl-2-methyl- tae, obtained from control and diabetic rats at the time of propiophenone; Upjohn), U46619 ((l5S)-hydroxy-1 la,9a- killing, were denuded of endothelial cells (as above) and the (epoxymethano) prosta-5Z, 13E-dienoic acid; Upjohn), 2-(2, tissues stored at - 80C until required. 6-dimethoxyphenoxyethyl) aminomethyl-1, 4-benzodioxane hydrochloride (WB-4101 HC1, Research Biochemicals Inc.). Phenylephrine was dissolved in catecholamine diluent Radioligand binding (0.312 g NaH2PO4 and 0.08 g ascorbic acid per litre of 0.9% (w/v) saline). Ketanserin was dissolved in dimethyl sulphox- Aortae from 8-10 diabetic or control rats were weighed and ide. Indomethacin was dissolved in 1% NaCO3. U46619 was suspended in 10 ml ice-cold Krebs phosphate buffer (KPB) of prepared in ethanol, which was evaporated under a stream of composition, (mM): NaCl 119, KCl 4.8, MgSO4 1.2, CaCl2 N2, and redissolved in distilled water. Further dilutions of 2.5, glucose 11.7, NaH2PO4 1.3 and Na2HPO4 8.7. The tissues these drugs, and stock solutions of all other drugs (except for were crudely chopped before being homogenized (12 s) in a phenylephrine), were prepared in distilled water. polytron (Kinematica PT 10-35). The chopped tissues were For binding experiments WB-4101, methysergide and 5-HT then homogenized in a glass homogenizer (4-6 strokes) prior were diluted in KPB containing 0.4% ascorbic acid, 40 tiM to centrifugation (30 g, 7 min, 40C; Sorvall model RC5C), iproniazid and 120 !LM of the catechol-O-methyl transferase passed through a double layer of gauze, centrifuged again inhibitor, U-0521 (Henseling, 1983). (45,000 g, 15 min, 4C), and the supernatant removed. The membrane pellet was resuspended (10 ml KPB) and allowed Statistics to equilibrate (O min, 37°C, to promote the breakdown of endogenous catecholamines). The suspension was cooled in Comparisons between responses in aortae from STZ-treated an ice-bath and spun again (45,000 g, 15 min, 4°C). The and control rats were made by two-way analysis of variance membrane pellets were resuspended in KPB (8-10 ml). Mem- (ANOVA). Multiple comparisons were analysed by Tukey's brane binding to [3H]-ketanserin (specific activity 60.0 Ci test. Values shown are means ± s.e.mean. Shifts between mmol', NEN Research Products) was carried out by incu- linear portions of concentration-response curves were cal- bating 100ILI of tissue homogenate (30-63 jg protein) with culated by the Apple Ile COMPAR programme. ECm values [3HJ-ketanserin for 10 min (37°C) in a final volume of 200 gIL.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Synthesis and Adrenolytic Activity of New Propanolamines
    Molecules 2010, 15, 3887-3904; doi:10.3390/molecules15063887 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Synthesis and Adrenolytic Activity of New Propanolamines Grażyna Groszek 1,*, Agata Bajek 1, Agnieszka Bis 1, Agnieszka Nowak-Król 1, Marek Bednarski 2, Agata Siwek 3 and Barbara Filipek 2,* 1 Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańców Warszawy Avenue, 35- 959 Rzeszów, Poland 2 Laboratory of Pharmacological Screening, Jagiellonian University Medical College, 9 Medyczna, 30-689 Kraków, Poland 3 Department of Pharmacobiology, Jagiellonian University Medical College, 9 Medyczna, 30-689 Kraków, Poland * Authors to whom correspondence should be addressed; E-Mails: [email protected] (G.G.); [email protected] (B.F.); Tel.: +48 17 8651751(G.G.); +48 126205531(B.F.); Fax: +48 17 8543655 (G.G.); +48 12 6205552 (B.F.). Received: 20 April 2010; in revised form: 23 May 2010 / Accepted: 26 May 2010 / Published: 28 May 2010 Abstract: The synthesis of (2R,S)-1-(6-methoxy-4-(methoxymethyl)-1H-indol-5-yloxy)-3- (2-(2-methoxyphenoxy)ethylamino)propan-2-ol and (2R,S)-1-(4-methoxy-6-(methoxy- methyl)-1H-indol-5-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol is described. The compounds were tested for electrographic, antiarrhythmic, hypotensive, and spasmolytic activity, as well as for α1-, α2- and β1-adrenoceptor binding affinity. Keywords: α1-andrenoceptor antagonist; synthesis; pharmacology 1. Introduction In our search for new aminopropan-2-ol derivatives with cardiovascular activity among, we obtained the compound (2R,S)-1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2- ol, (R,S)-9 (Figure 1) [1] which became a lead structure for further investigations.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Dose-Dependent Cx1-Adrenoceptor Antagonist Activity of the Anti-Arrhythmic Drug, Abanoquil (UK-52,046), Without Reduction in Blood Pressure in Man
    Br. J. clin. Pharmac. (1992), 33, 405-409 Dose-dependent cx1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man TONY C. K. THAM, SUZANNE GUY, ROBIN G. SHANKS & DEAN W. G. HARRON Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Belfast, Northern Ireland 1 The dose-dependency of the co1-adrenoceptor antagonist activity of the anti-arrhythmic abanoquil (UK-52,046) was investigated in 10 healthy male subjects who received serially increasing infusions of phenylephrine before and 2, 4, 8, 12, 24 and 48 h after single oral doses of abanoquil 0.25, 0.5 and 1 mg and placebo in a double-blind randomised manner. 2 The doses of phenylephrine required to increase systolic BP by 20 mm Hg (PS20) were calculated using a quadratic fit to the individual dose-response curves. 3 Abanoquil 0.25, 0.5 and 1 mg increased the PS20 in a dose-dependent manner with effects which were maximal at 2 to 8 h and lasted for 24 to 48 h (P < 0.05). Maximal dose ratios were: abanoquil 0.25 mg 2.0 ± 0.9, 0.5 mg 2.4 ± 1.3, 1 mg 3.4 ± 1.1. 4 No change occurred in supine BP but a small increase (P < 0.01) occurred in supine HR 8 h post-dosing (64 ± 9, 58 ± 6 beats min-1 for abanoquil 1 mg and placebo respectively). 5 Therefore abanoquil 0.25, 0.5 and 1 mg showed dose-dependent otl-adrenoceptor antagonist activity with no effect on supine BP.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao Et Al
    USOO8637524B2 (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao et al. (45) Date of Patent: Jan. 28, 2014 (54) PYRIMIDINONE INHIBITORS OF Tonn, Biological Mass Spectrometry vol. 22 Issue 11, pp. 633-642 LIPOPROTEIN-ASSOCATED (1993).* PHOSPHOLPASE A2 Hist Biomedical Spectrometry vol. 9 Issue 7, pp. 269-277 Wolen, Journal of Clinical Pharmacology 1986; 26: 419-424.* (75) Inventors: Tadimeti Rao, San Diego, CA (US); Browne, Journal of Clinical Pharmacology 1998; 38: 213-220.* Chengzhi Zhang, San Diego, CA (US) Baillie, Pharmacology Rev. 1981: 33:81-132.* Gouyette, Biomedical and Environmental Mass Spectrometry, vol. (73) Assignee: Auspex Pharmaceuticals, Inc, La Jolla, 15, 243-247 (1988).* CA (US) Cherrah, Biomedical and Environmental Mass Spectrometry vol. 14 Issue 11, pp. 653-657 (1987).* Pieniaszek, J. Clin Pharmacol. 1999; 39: 817-825.* (*) Notice: Subject to any disclaimer, the term of this Honma et al., Drug Metab Dispos 15 (4): 551 (1987).* patent is extended or adjusted under 35 Kushner, D. Jet al., Pharmacological uses and perspectives of heavy U.S.C. 154(b) by 58 days. water and deuterated compounds, Can. J. Physiol. Pharmacol. (1999), 77, 79-88. (21) Appl. No.: 12/840,725 Bauer et al., Influence of long-term infusions on lidocaine kinetics, Clin. Pharmacol. Ther. (1982), 31(4), 433-7. (22) Filed: Jul. 21, 2010 Borgstrom et al., Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect, J Pharm. Sci., (1988), 77(11) 952-4. (65) Prior Publication Data Browne et al., Chapter 2. Isotope Effect: Implications for pharma US 2011/0306552 A1 Dec.
    [Show full text]
  • Keyword Index to Volume 12
    International Journal of Impotence Research (2000) 12, 346±347 ß 2000 Nature Publishing Group All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Keyword Index to Volume 12 Abanoquil Suppl 1 S37 Cardiovascular disease Drug development Fibrosis 111 Acquired curvature 289 Suppl 4 S147 Suppl 4 S158 Forskolin Suppl 1 S41 Adrenalin 312 Cardiovascular risk Drug therapy Suppl 4 Functional antagonism Adrenergic receptors Suppl 4 S6 S59 Suppl 4 S39 Suppl 4 S34 Cavernosal expandabil- Duplex ultrasound 59 Adverse events Suppl 4 ity 328 Gene therapy Suppl 4 S53 Central nervous system Ef®cacy 97 S163 Age 143 Suppl 1 S13, Suppl 4 Glans penis 195 Electromotive drug de- 0 0 Alcoholism 47 S67 livery Suppl 4 S86 3 ,5 -cyclic-GMP phos- Alpha-adrenergic ago- cGMP Suppl 4 S34 Engorgement 235 phodiesterase inhibi- nist 59 cGMP-dependent kinase eNOS 213 tors 177 Alpha adrenergic an- I157 EP peptides 255 Gonadotropin releasing tagonist Suppl 1 S26 Clinical diagnosis Suppl EP receptor 107 hormone 269 Alpha adrenergic recep- 4 S119 Epidemiologic methods Growth hormone (GH) tor Suppl 1 S20, Clitoris 111, 235 197 releasing peptides 255 Suppl 1 S41, Suppl 1 CNS pharmacology Epidemiology 305 Haemoglobin 213 S48 Suppl 4 S26, Suppl 4 Erectile dysfunction 23, Helicine arterioles 33 Alpha adrenoceptors S163 41, 47, 83, 97, 103, High-¯ow priapism Suppl 1 S5 Colchicine 169 107, 143, 147, 165, Suppl 4 S133 Alpha-1 adrenoceptor Collagen Suppl 4 S39 191, 197, 223, 263, Histamine antagonist 59 antagonist Suppl 1 S37 Collagen disease mar- 273, 279, 279, 305, HLA antigens
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]